Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 3:30 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 1,141 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Isotonic solution Clear all

Conditions: Quality of Recovery, Same Day Surgery, Nausea and Vomiting, Postoperative, Vaginal Prolapse
Interventions: Dexamethasone, Normal saline; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Weston, Florida

Conditions: Alzheimer's Disease
Interventions: Placebo, octagam 10%; Drug · Biological
Lead sponsor: Octapharma; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Hoboken, New Jersey

Conditions: Pediatric Burns
Interventions: magnesium sulfate, Normal Saline (0.9% NaCl); Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 3 Years to 18 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Juvenile Idiopathic Arthritis (JIA)
Interventions: allogeneic Hope Biosciences adipose-derived mesenchymal stem cells, Normal Saline Solution 0.9%; Biological · Other
Lead sponsor: Hope Biosciences Research Foundation; Industry
Eligibility: 2 Years to 16 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Sugar Land, Texas

Conditions: Psychosis, Schizophrenia, Schizoaffective Disorder
Interventions: ceftriaxone, Normal Saline; Drug
Lead sponsor: Research Foundation for Mental Hygiene, Inc.; Other
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Aortic Aneurysm, Thoracic
Interventions: Nicardipine, 0.9% saline; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes (DM), Diabetic Ketoacidosis, Ketosis Prone Diabetes, Hyperglycaemia (Diabetic)
Interventions: Arginine hydrochloride, Sodium Chloride 0.9%; Drug
Lead sponsor: David K Carroll; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Stress Disorders, Post-Traumatic
Interventions: Ropivacaine injection, Normal saline; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Fort Hood, Texas • San Antonio, Texas

Conditions: Genital Herpes Simplex Type 2
Interventions: BNT163, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more

Conditions: Intracranial Aneurysm, Brain Edema, Scoliosis, Surgery
Interventions: Phenylephrine, Epinephrine, Albumin, Voluven, Normal Saline, Packed Red Blood Cells, FloTrac Monitor; Drug · Other · Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 15 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Methamphetamine Abuse
Interventions: normal saline, ch-mAb7f9; Biological
Lead sponsor: InterveXion Therapeutics, LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Euglycemia, Hypoglycemia, Hyperglycemia
Interventions: Exenatide 0.27 ng/kg/min, Exenatide 0.41 ng/kg/min, Placebo; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Postural Tachycardia Syndrome
Interventions: Saline, Placebo; Drug · Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2031
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autonomic Nerve Block
Interventions: Pecto-intercostal Fascial Block with 20 ml of 0.35% ropivacaine, Pecto-intercostal Fascial Block with normal saline; Procedure
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Anesthesia, Neuromuscular Blockade
Interventions: Saline 0.06 ml/kg, Rocuronium 0.2 mg/kg, Rocuronium 0.4 mg/kg, Rocuronium 0.6 mg/kg; Drug
Lead sponsor: Medtronic - MITG; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Cesarean Section Complications, Cesarean Section; Infection
Interventions: Irrisept, Normal Saline; Device · Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Pain
Interventions: Dexmedetomidine, Normal Saline; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Primary Sclerosing Cholangitis
Interventions: Mitomycin C, Normal saline; Drug
Lead sponsor: Li, Zhiping, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Infant, Extremely Premature, Acute Lung Injury, Chronic Lung Disease of Prematurity, Budesonide
Interventions: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL), Infants in the control group (S/P group) receive placebo (Normal saline 1mL); Drug
Lead sponsor: University of Arizona; Other
Eligibility: Up to 18 Hours
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Rheumatoid Arthritis
Interventions: MEDI-522, Placebo; Biological · Other
Lead sponsor: MedImmune LLC; Industry
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 29
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 24 more

Conditions: Neurocognitive, Neuroprotective, Neonatal, Neurodevelopmental Impairment
Interventions: Darbepoetin, Placebo; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 1 Hour to 24 Hours
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 16
States / cities: Birmingham, Alabama • Palo Alto, California • Atlanta, Georgia + 12 more

Conditions: Post Operative Pain
Interventions: 0.25% bupivicaine will be injected at the study port site prior to incision, Saline will be injected at the study port site prior to incision, Saline will be in injected into the port site prior to closure, 0.25% bupivicaine will be injected into the port site prior to closure; Drug
Lead sponsor: Stony Brook University; Other
Eligibility: 21 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stony Brook, New York

Conditions: Immunization; Infection|Transplantation Infection|Influenza, Influenza
Interventions: Fluzone High Dose Inactivated Influenza Vaccine, Fluzone Standard Dose Inactivated Influenza Vaccine; Biological
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Osteoarthritis
Interventions: Povidone iodine, Vancomycin powder, Conventional; Drug · Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 100 Years
Enrollment: 2,129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 14
States / cities: Rancho Mirage, California • Denver, Colorado • Weston, Florida + 6 more

Search by objective public record fields.

Dexamethasone Administration To Improve Patient Recovery In Ambulatory Vaginal Prolapse Surgery: Is There A Role?

Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's Disease

Magnesium Sulfate in Pediatric Burn Dressing Changes

HB-adMSCs vs Placebo for the Treatment of Juvenile Idiopathic Arthritis

A Placebo-controlled Efficacy Study of IV Ceftriaxone for Refractory Psychosis

NICardipine Neuroprotection in AortiC Surgery (NICNACS)

Phase 1 Trial of Arginine Hydrochloride for the Management of Diabetic Ketoacidosis in Type 2 Diabetes

Combining Stellate Ganglion Block With Prolonged Exposure for PTSD

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Goal-Directed Intraoperative Fluid Management Using FloTrac© Monitoring in High-Risk Neurosurgical Patients

Safety Study of Ch-mAb7F9 for Methamphetamine Abuse

Intravenous Exenatide (Byetta) During Surgery

Intravenous (IV) Saline and Exercise in Postural Tachycardia Syndrome (POTS)

Sternotomy PIFB Block in Open Heart Surgery

The Effect of Neuromuscular Blockade on the Composite Variability Index (CVI) During Laryngoscopy

Wound Irrigation With Saline Versus Hypodilute-chlorhexidine After Cesarean Section (WISHES Study)

Evaluation of Dexmedetomidine on Post-operative Narcotic Requirements and Pain Scores in Bariatric Patients

Mitomycin C Therapy for Patients With Primary Sclerosing Cholangitis

Intra-tracheal Instillation of Budesonide to Prevent Chronic Lung Disease

Effects of MEDI-522 On Disease Activity and Progression of Joint Damage in Patients With Active Rheumatoid Arthritis Suboptimally Responding to Methotrexate

Darbepoetin Trial to Improve Red Cell Mass and Neuroprotection in Preterm Infants

Study to Compare Reduction in Pain After Surgery With and Without Local Anesthesia During Laparoscopy

High vs. Standard Dose Influenza Vaccines in Lung Transplant (Repeater)

Vancomycin Powder and Dilute Povidone Iodine Lavage for Infection Prophylaxis in High Risk Total Joint Arthroplasty